12/04/2022at 08:39

Lundbeck sues competitor for infringing on patent rights

Lundbeck and Otsuka are alleging that pharmaceutical firm Viatris’s proposed drug is in violation of eight patents.

by marketwire, translated by daniel pedersen

Pharmaceutical firm Lundbeck has filed a lawsuit in the US against Viatris for violating the patent protection of schizophrenia drug Abilify Maintena, Bloomberg News reports.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

Access all locked articles
Receive our daily newsletters
Access our app

Get full access for you and your coworkers

Start a free company trial today

Lundbeck preps for war against generic drugmakers in US
For subscribers
Novo Nordisk initiates patent suit to stop Ozempic copies
For subscribers
Genmab loses royalties case against Janssen
For subscribers

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Front page now

Initial probes pointed to the contamination coming from the capsules containing Dicillin, or the drug's packaging | Foto: Lægemiddelstyrelsen / Pr

Other

Production at contaminated CMO continues – authorities deny further risks

The Danish Medicines Agency says shutting down the one production line specifically making the contaminated Dicillin is adequate, although the root cause is still unknown.

For subscribers

Glenn Saldanha is chairman at the board of Glenmark | Foto: Danish Siddiqui/Reuters/Ritzau Scanpix

Pharma & biotech

Indian generic drugmaker to launch Leo Pharma copycat drug in US

For subscribers

Regulation

EU delays new drug law proposal

For subscribers

Pharma & biotech

Obesity drug hit makes Novo Nordisk more valuable than Nestle

For subscribers

Pharma & biotech

Novo Nordisk enters collaboration with AI-driven drug discovery company

For subscribers

Pharma & biotech

Novo Nordisk reaches primary endpoint in phase III study of oral semaglutide

For subscribers

Less than one in five Novo Nordisk execs is a woman – chairman expects change over time

The very top of the Danish drugmaker has only grown more distant to its own goal of ensuring 45% male/female representation across leadership teams.

For subscribers

Pharma & biotech

Novo Nordisk denies Danish stealth marketing, admits to carrying responsibility for grant usage

One of the Danish drugmaker’s partnered patient organizations did not disclose ties to Novo Nordisk in promotional material for obesity treatment.

For subscribers

Helge Lund, chairman at the board of directors at Novo Nordisk | Foto: Christopher Due Karlsson / Medwatch

Pharma & biotech

Novo Nordisk board discussed supply issues at every meeting in 2022

How to meet surging demand for some of the Danish drugmaker’s most popular drugs was amongst the most debated topics at the year’s board meetings, Chair Helge Lund says.

For subscribers

Lundbeck sues competitor for infringing on patent rights

Read the whole article

With your free trial you get:

Get full access for you and your coworkers

Related articles:

Lundbeck preps for war against generic drugmakers in US

Novo Nordisk initiates patent suit to stop Ozempic copies

Genmab loses royalties case against Janssen

Sign up for our newsletter

Front page now

Production at contaminated CMO continues – authorities deny further risks

Indian generic drugmaker to launch Leo Pharma copycat drug in US

EU delays new drug law proposal

Obesity drug hit makes Novo Nordisk more valuable than Nestle

Novo Nordisk enters collaboration with AI-driven drug discovery company

Novo Nordisk reaches primary endpoint in phase III study of oral semaglutide

Further reading

Less than one in five Novo Nordisk execs is a woman – chairman expects change over time

Novo Nordisk denies Danish stealth marketing, admits to carrying responsibility for grant usage

Novo Nordisk board discussed supply issues at every meeting in 2022

Jobs